Silobreaker: BRIEF-Elan Corp reports Tysabri Phase 3 subset dat...

Shares in Elan plunged 20pc to ?3.42 in Dublin yesterday after its multiple sclerosis treatment Tysabri was linked to over 20 cases of a potentially fatal brain disease and the European drug watchdog said it was reviewing its use. Elan finished at ?3.42 ... [Irish Independent - 10/24/2009]

Entities: Tysabri, Bapineuzumab, Alzheimer's Disease

First Reported 10/21/2009 - Updated 10/21/2009 - 3 Documents (in Health)

Johnson & Johnson

Elan pins hopes on multiple sclerosis drug

Kelly Martin, chief executive of Elan, said the Irish drugs group would focus on increasing sales of its multiple sclerosis drug Tysabri, following the sale of a stake in the business to Johnson & Johnson last month.Tysabri, which accounts for two-thirds ... [Cafepharma - 10/21/2009]

Entities: Multiple Sclerosis, Tysabri, Kelly Martin, Johnson & Johnson

First Reported 10/21/2009 - Updated 10/21/2009 - 2 Documents

Biogen sinks on new worry over Tysabri

Biogen Idec has reported third-quarter earnings that topped expectations, but concern over the future of its multiple sclerosis drug Tysabri sent its shares down more than 2 percent.Revenue from sales of Tysabri rose 21 percent to USD 207 million in the ... [Ireland Business World - 10/21/2009]

Entities: Tysabri, Geoffrey Meacham, Avonex

Change Password

Log in to Silobreaker

Advanced Search Options

BRIEF-Elan Corp reports Tysabri Phase 3 subset data